Russell Frank Company’s TG Therapeutics TGTX Stock Holding History

Russell Frank Company’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-119,079	Closed	-$1.98M	–	3055
2015 Q2	$1.98M	Buy	119,079 +3,958	+3%	+$62.7K	﹤0.01%	1977
2015 Q1	$1.78M	Sell	115,121 -39,569	-26%	-$599K	﹤0.01%	1837
2014 Q4	$2.44M	Buy	154,690 +78,132	+102%	+$1.02M	﹤0.01%	1670
2014 Q3	$817K	Buy	+76,558	New	+$710K	﹤0.01%	2153
2013 Q4	–	Sell	-7,025	Closed	-$42K	–	3039
2013 Q3	$42K	Buy	7,025 +68	+1%	+$416	﹤0.01%	3140
2013 Q2	$44K	Buy	+6,957	New	+$44.6K	﹤0.01%	2893

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Russell Frank Company's TGTX Position: Q3 2015 in Review

Russell Frank Company sold out of TG Therapeutics (TGTX) in Q3 2015, closing a stake of 119,079 shares — an estimated $1.98M sold.

Russell Frank Company first reported a position in TGTX in Q2 2013 and held it in 6 quarters. The position peaked at $2.44M in Q4 2014. 83 funds tracked by Wall St. Rank hold TGTX as of Q3 2015.

Russell Frank Company reported no remaining TG Therapeutics position as of Q3 2015 after selling out during the quarter.
Russell Frank Company sold 119,079 TG Therapeutics shares in Q3 2015, an estimated $1.98M.
Russell Frank Company first reported a position in TG Therapeutics in Q2 2013 and held it in 6 quarters.
Russell Frank Company's TG Therapeutics position peaked at $2.44M in Q4 2014.
83 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2015.

Based on Russell Frank Company's 13F filing for Q3 2015, filed 23 Oct 2015.